In this KOD case study, we break down how Kodiak Sciences turned a major Phase 3 clinical trial catalyst into a nearly 200% intraday move, including the pre-market price action, multi-timeframe breakout, elevated short interest, and 6-9-12 EMA structure. You’ll also see how the setup fits into momentum and breakout trading, why waiting for confirmation still left substantial upside, and what KOD teaches us about finding powerful trades outside traditional earnings catalysts.
Want to learn more about identifying and trading powerful momentum moves? This book is a useful companion for traders studying breakout setups, catalysts, and rapidly moving stocks.
Kodiak Sciences Inc. (KOD) delivered one of the most extreme momentum moves of 2026 when shares surged nearly 200% intraday following positive Phase 3 clinical trial results.
Kodiak is a pre-commercial biotechnology company focused primarily on treatments for retinal diseases.
On September 25, 2026, the company announced that it would release topline results from its DAYBREAK Phase 3 trial evaluating Zenkuda and KSI-501 in patients with wet age-related macular degeneration.
Three days later, Kodiak announced that both drugs had successfully met the trial’s primary endpoints.
Shares exploded higher during pre-market trading and continued climbing throughout the regular trading session. By the closing bell, KOD had gained 177.96%, while its intraday high represented a gain approaching closer to 200% from the previous day’s close.
The move transformed Kodiak almost overnight.
Based on approximately 62.8 million shares outstanding, the company’s market capitalization increased from roughly $2.0 billion before the announcement to more than $5.6 billion at the September 28 close, adding more than $3 billion in market value in a single trading session.
Want to learn more about identifying and trading powerful momentum moves? This book is a useful companion for traders studying breakout setups, catalysts, and rapidly moving stocks.
Quick Answer: Why Did Kodiak Sciences Inc. Move Nearly 197% Higher in a Single Trading Day?
Kodiak Sciences (KOD) surged nearly 197% at its September 28, 2026 intraday peak after positive Phase 3 DAYBREAK trial results sent the stock from roughly $32 to more than $95. From the close of the 6 a.m. hourly catalyst candle, KOD still delivered an 80.2% MFE versus just -6.95% MAE, remained above its 6-9-12 hourly EMAs, and finished the session roughly 69% above the hypothetical entry, while the company added more than $3 billion in market capitalization in a single trading day.
KOD Fundamentals & Catalyst
Kodiak Sciences is a Palo Alto-based biotechnology company focused on developing treatments for retinal diseases that can cause blindness.
Importantly, Kodiak was still a pre-commercial biotechnology company when the DAYBREAK results were announced. That makes clinical trial results particularly important because the company’s valuation depends heavily on whether its pipeline can eventually produce commercially viable drugs.
The company’s pipeline includes Zenkuda, KSI-501 and KSI-101, with multiple late-stage clinical programs underway. Kodiak has identified an approximately $15 billion anti-VEGF market across retinal vascular diseases as the commercial opportunity targeted by Zenkuda and KSI-501.
Before the DAYBREAK catalyst, KOD closed September 25 at approximately $32.35 per share, giving the company a market capitalization of roughly $2.03 billion.
Short interest was also unusually high heading into the catalyst.
Reported figures vary depending on the provider and calculation methodology, but Finviz reported about a roughly 18.35% short float, while MarketBeat reported approximately 10.67 million shares sold short as of September 15, equal to roughly 30.5% of the public float.
That matters enormously for a momentum setup.
When a heavily shorted biotechnology stock suddenly produces substantially better clinical news than bearish traders expected, short sellers may be forced to buy shares to close their positions.
That additional demand can accelerate an already powerful news-driven rally, and in my opinion, that’s exactly what led to KOD’s +177% intraday move.
KOD Technical Analysis & Outcome
The KOD move actually started several days before the regular-session explosion.
At approximately 6 p.m. on September 25, KOD suddenly surged as much as 27% during a single hourly candle before retracing and finishing the hour approximately 11% above its opening price.
There is a straightforward explanation for that first move.
At 6:01 p.m. ET, Kodiak publicly announced that it would release topline DAYBREAK Phase 3 results before the market opened on September 28. The stock’s after-hours surge therefore appears to have occurred in direct response to that announcement rather than requiring any assumption that confidential trial results had leaked beforehand.
Trading then became relatively quiet through the remainder of the evening and early pre-market period.
That changed dramatically Monday morning.
At 6:30 a.m. ET on September 28, Kodiak announced that both Zenkuda and tabirafusp alfa tedromer, also known as KSI-501, met the primary endpoints of the DAYBREAK Phase 3 trial.
Zenkuda produced meaningful vision gains while demonstrating rapid retinal drying and significant durability. Kodiak reported that 54% of patients were able to reach a six-month dosing interval under the trial’s retreatment criteria. KSI-501 also met its primary vision endpoint and key anatomical secondary endpoint. Kodiak Sciences Inc.
Wall Street clearly viewed the results as materially positive. During the 6 a.m. hourly candle, KOD surged as much as 73% from the candle’s opening price, ultimately finishing the hour approximately 56% higher.
By the close of that candle, KOD was already roughly 63% above its previous regular-session closing price. For this case study, that hourly candle close represents the hypothetical momentum entry.
- A major fundamental catalyst had just been released.
- The reaction to the catalyst was overwhelmingly positive.
- KOD had broken out on the hourly, four-hour and daily charts .
- Short interest was elevated , creating additional potential fuel for the move.
- Price had already demonstrated extraordinary pre-market momentum .
- The move was not simply a one-candle spike that immediately collapsed.
Once regular trading opened, buyers continued pushing KOD higher throughout the entire trading session. From the hypothetical entry at the close of the catalyst candle, the stock produced an 80.2% intraday MFE while experiencing only -6.95% MAE.
Even more importantly for the strategy being tested, KOD remained above its 6, 9 and 12-period hourly exponential moving averages throughout the trading session.
There were pullbacks, but momentum never meaningfully broke down.
Using an end-of-day exit rather than attempting to predict the intraday top would still have produced a gain of approximately 69% from the hypothetical entry price.
KOD ultimately finished the regular session at $89.92, up 177.96% from its previous close, after trading more than 38 million shares compared with an average trading volume below one million shares.
Key Takeaways – Kodiak Sciences Inc Case Study
KOD shows that some of the strongest momentum setups can come from non-earnings catalysts when the news materially changes how the market values a company.
Positive Phase 3 results triggered a multi-timeframe breakout, collided with elevated short interest, and pushed Kodiak’s market cap from roughly $2 billion to more than $5 billion in a single session.
Just as importantly, traders did not need to catch the first spike.
Even after waiting for the 6 a.m. catalyst candle to close, KOD still produced an 80.2% MFE while holding above its short-term hourly EMAs.
The bigger lesson is that strong catalysts, technical confirmation, and sustained price acceptance can leave plenty of opportunity even after the initial move has already begun.
Want to Get Better at Spotting Moves Like KOD Before the Momentum Is Gone?
Case studies are useful, but the real edge comes from understanding why momentum builds, how breakouts develop, and what separates a genuine catalyst-driven move from a stock that is simply spiking and fading.
If you want to sharpen your approach to momentum trading, breakout setups, risk management, and fast-moving stocks, this is a worthwhile addition to your trading library. At just $16.99, it is a relatively inexpensive way to add another perspective to the way you study setups like KOD.
If you want to go deeper:
- Explore the Trading Statistics Hub to understand how different sectors behave across market cycles
- Study real setups inside the Trade Reviews section
- Learn the framework behind high-probability setups in the Post-Earnings Momentum Strategy
This is how you turn raw market data into repeatable trading edge.
Frequently Asked Questions About Kodiak Sciences (KOD)
Is Kodiak Sciences a good investment?
Whether Kodiak Sciences is a good investment depends largely on an investor’s tolerance for clinical-stage biotechnology risk. The successful DAYBREAK Phase 3 results significantly improved the outlook for Zenkuda and KSI-501, but Kodiak still faces regulatory, commercialization and competitive risks. Its valuation is now also substantially higher following the September 2026 rally, so future returns will depend on FDA progress, additional clinical results and whether its drugs can successfully compete in the retinal disease market. Kodiak Sciences
What does Kodiak Sciences do?
Kodiak Sciences is a biotechnology company developing treatments for retinal diseases that can cause vision loss and blindness. Its pipeline includes Zenkuda, KSI-501 and KSI-101, with programs targeting wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vein occlusion and other retinal conditions. Kodiak Sciences
Why did Kodiak Sciences stock drop?
Kodiak Sciences has suffered several major historical declines following disappointing clinical trial results. In February 2022, shares plunged roughly 80% after KSI-301 failed to meet the primary endpoint of the DAZZLE wet-AMD trial. The stock was hit again in 2023 after the GLEAM and GLIMMER Phase 3 trials failed their primary endpoints, with Kodiak reporting an unexpected increase in cataracts among treated patients. Fierce Biotech
What is the current stock price of Kodiak Sciences?
As of September 29, 2026, KOD was trading around $91 per share, following its historic September 28 rally. The stock closed the previous session at $89.92, up 177.96%, after reaching an intraday high of $95.77. Stock prices change continuously during market hours, so the live quote may differ. MarketBeat
How often do stocks make moves of more than 100% or 200% in a single day?
Moves of 100% or more in a single trading day are extremely unusual, particularly among companies already worth billions of dollars. They are more commonly seen in small-cap stocks following major catalysts such as clinical trial results, FDA decisions, acquisitions or other events that dramatically change expectations. A nearly 200% intraday move like KOD’s is therefore an extreme example of catalyst-driven momentum rather than a normal daily stock-market fluctuation.
Why did Kodiak Sciences stock surge in September 2026?
KOD surged after Kodiak announced that Zenkuda and KSI-501 met the primary endpoints of the DAYBREAK Phase 3 trial in wet age-related macular degeneration. Zenkuda’s durability was particularly notable, with 54% of patients reaching six-month dosing intervals, helping drive a dramatic reassessment of the potential commercial value of Kodiak’s pipeline. Barron’s
Was KOD a short squeeze?
Short covering may have amplified KOD’s rally, but the move had a clear fundamental catalyst behind it. Positive Phase 3 results triggered the initial repricing, while elevated short interest potentially added further buying pressure as bearish traders closed positions during the breakout.
Leave a Reply